Concerns over counterfeit drugs have emerged once again in the country. The Central Drugs Standard Control Organisation (CDSCO) has launched an investigation after suspicions arose regarding a specific batch of buprenorphine injection used for pain management.
Buprenorphine is used for severe post-surgical pain, intense cancer-related pain, and chronic complex pain relief. According to government sources, the 'LM1889' batch of 2-milliliter vials of buprenorphine injection is preliminarily suspected to be 'spurious' or counterfeit. This batch was manufactured in December 2023 and will expire in November 2029. A central directive has been issued to temporarily suspend the use of drugs from this batch.
Also Read | 21 Indian crew safe after ships attacked in Strait of Hormuz amid rising tensions, confirms govt
According to medical experts, buprenorphine is a powerful opioid-class drug commonly used to control severe to moderate pain, particularly post-surgery, cancer-related pain, or chronic complex pain. Additionally, this drug plays an important role in modern medicine for addiction treatment. Buprenorphine is used as part of 'substitution therapy' to reduce opioid dependency, helping to minimize sudden 'withdrawal syndrome' symptoms in patients and gradually reducing dependency.
Company denies manufacturing batch
The CDSCO report clearly states that the company whose name appears on the label of the 'LM1889' batch has claimed they never manufactured that batch of injections. This naturally strengthens suspicions of fraud. According to drug regulatory authorities, if any drug is brought to market using another company's name or is manufactured as a counterfeit of genuine medicine, it is classified as a 'spurious drug'. Provisions regarding this exist in the Drugs and Cosmetics Act of 1940.
Also Read | Why is humid heat becoming more dangerous than heatwaves in India?
Concerns about the quality of various types of drugs have been steadily increasing over the past few months. In March, a higher number of drug batch samples across the country were identified as 'Not of Standard Quality' (NSQ) compared to the monthly average, and one sample was also suspected to be counterfeit, which includes this buprenorphine injection.
According to a large section of health experts, such incidents are not only dangerous for patient safety but also raise questions about trust in the entire healthcare system. Therefore, demands are being raised from various quarters to complete the investigation quickly and take strict action against the culprits. CDSCO has already begun a detailed investigation into the matter. Central authorities have stated that decisions regarding further steps will be made once the investigation report is published.
